



## Sunil Arani Reddy

Clinical Associate Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC2232

MC 6501

Stanford, CA 94305

Tel (650) 736-1234      Fax (650) 736-1373

### Bio

---

#### CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- lymphoma/melanoma/cutaneouslymphoma
- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

#### PROFESSIONAL EDUCATION

- Medical Education: University of California at Irvine School of Medicine (1994) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2000) CA
- Residency: University of Michigan Health System Internal Medicine Residency (1997) MI
- Internship: University of Michigan Health System Internal Medicine Residency (1995) MI

#### LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

### Research & Scholarship

---

#### CLINICAL TRIALS

- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma, Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma, Not Recruiting

- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma, Not Recruiting
- A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma, Not Recruiting
- A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma, Not Recruiting
- A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors, Not Recruiting
- A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201), Not Recruiting
- A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma, Not Recruiting
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma, Not Recruiting
- A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma, Not Recruiting
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma, Not Recruiting
- A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma, Not Recruiting
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma, Not Recruiting
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma, Not Recruiting
- A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer, Not Recruiting
- A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Not Recruiting
- An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma, Not Recruiting
- An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma, Not Recruiting
- Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin, Not Recruiting
- Compassionate Use Trial for Unresectable Melanoma With Ipilimumab, Not Recruiting
- Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery, Not Recruiting
- Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma, Not Recruiting
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma, Not Recruiting
- ITIL-168 in Advanced Melanoma, Not Recruiting
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors, Not Recruiting
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma, Not Recruiting
- PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy, Not Recruiting
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer, Not Recruiting
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma, Not Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Not Recruiting
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery, Not Recruiting
- Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma, Not Recruiting
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma, Not Recruiting

- Safety Study of MGD009 in B7-H3-expressing Tumors, Not Recruiting
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL, Not Recruiting
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma, Not Recruiting
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL, Not Recruiting
- Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629), Not Recruiting
- Study of the Safety, Pharmacokinetics and Efficacy of Tinstamustine in Patients With Advanced Solid Tumors., Not Recruiting
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial, Not Recruiting
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery, Not Recruiting
- PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA), Not Specified

## Publications

---

### PUBLICATIONS

- **Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.** *JCO oncology practice*  
Othus, M., Truong, T. G., Sharon, E., Kendra, K., Grossmann, K., Buchbinder, E., Khushalani, N. I., Eroglu, Z., Chandra, S., Doolittle, G. C., Kirkwood, J. M., Ikeguchi, A., Mihalciou, et al  
2026: OP2501413
- **Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.** *Cancers*  
Alban, J., Bowen, R. C., Reichstein, D. A., McKean, M., Lutzky, J., Weis, E., Carvajal, R. D., Dulka, S., Morse, B. G., Butler, M. O., Rapisuwon, S., Kim, K. B., Chandrasekaran, et al  
2025; 18 (1)
- **Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.** *Journal of cancer research and clinical oncology*  
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelmann, D. J., Glazer, E. S., Ejaz, A., Richtig, E., Ochsenreither, S., Reddy, S. A., Lowe, M. C., Beasley, G. M., Gesierich, et al  
2025; 152 (1): 25
- **Molecularly Targeted Cancer Medications and Kidney Health.** *JAMA network open*  
Ziolkowski, S., Long, J., Zhong, Y., Morgan-Cooper, H., Wakelee, H., Khaki, A., Riaz, F., Reddy, S., Leonard, M., Anand, S.  
2025; 8 (11): e2541221
- **Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management.** *Journal of the American Academy of Dermatology*  
Akaike, T., Thakuria, M., Silk, A. W., Hippe, D. S., Ch'en, P. Y., Park, S. Y., Urman, N. M., Chiu, M. W., Kim, H., Kim, E. Y., Hall, E. T., Bhatia, S., Reddy, et al  
2025
- **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.** *JACC. CardioOncology*  
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al  
2025
- **Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC).**  
Brohl, A., Burgess, M., In, G., Khaddour, K., O'Neill, P. M., Reddy, S. A., Whitman, E. D., Bianco, J. A.  
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS9603
- **An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.** *Annals of surgical oncology*  
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelmann, D. J., Glazer, E. S., Ejaz, A., Howard, J. H., Richtig, E., Ochsenreither, S., Reddy, S. A., Lowe, M. C., Beasley, et al  
2025

- **The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor.** *European journal of cancer (Oxford, England : 1990)*  
Shatila, M., Cruz, C. C., Lu, L., Abdul-Baki, K., Baerman, E., Takigawa, K., Rivera, A. U., Lee, I. J., Ngo, S., Sperling, G., Aleem, A. S., Menon, R., Sullivan, et al  
2025; 221: 115405
- **Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec.** *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]*  
Che, Y., Abou-Taleb, F., Reddy, S. A., Chang, A. L.  
2025
- **A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.** *Clinical case reports*  
Egoryan, G., Zimmet, A., Yu, M., Pozdol, J., Subramanian, A., Reddy, S., Nelson, J.  
2024; 12 (12): e9632
- **Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Thompson, J. A., Schneider, B. J., Brahmer, J., Abu Zaid, M., Achufusi, A., Armand, P., Berkenstock, M. K., Bermas, B., Braaten, T., Budde, L. E., Chokshi, S., Crees, Z. D., Davies, et al  
2024; 22 (9): 582-592
- **Abscopal Effect in Metastatic Melanoma: Generating Clinical Insights From Radiation-Induced Immune Response.** *Cureus*  
Nguyen, D. M., Phan, B. N., Reddy, S. A.  
2024; 16 (11): e72853
- **MEK Pathway Inhibitor-Mediated Response in BRAF V600-Mutant Melanoma with Brain Parenchymal and Leptomeningeal Metastases.** *Annals of neurology*  
Alhusaini, S., Naya, L., Reddy, S. A., Patel, C. B.  
2024
- **Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Akaike, T., Thakuria, M., Silk, A. W., Hippe, D. S., Park, S. Y., So, N. A., Maloney, N. J., Gunnell, L., Eschholz, A., Kim, E. Y., Sinha, S., Hall, E. T., Bhatia, et al  
2024: JCO2302054
- **Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.** *Annals of surgical oncology*  
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelmann, D. J., Glazer, E. S., Ejaz, A., Howard, J. H., Richtig, E., Ochsenreither, S., Reddy, S. A., Lowe, M. C., Beasley, et al  
2024
- **Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results**  
Zager, J. S., Orloff, M. M., Ferrucci, P., Choi, J., Eschelmann, D. J., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Reddy, S. A., Lowe, M. C., Beasley, G., Gesierich, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study.** *Annals of surgical oncology*  
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelmann, D. J., Glazer, E. S., Ejaz, A., Howard, J. H., Richtig, E., Ochsenreither, S., Reddy, S. A., Lowe, M. C., Beasley, et al  
2024
- **Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.** *Annals of surgical oncology*  
Zager, J. S., Orloff, M., Ferrucci, P. F., Choi, J., Eschelmann, D. J., Glazer, E. S., Ejaz, A., Howard, J. H., Richtig, E., Ochsenreither, S., Reddy, S. A., Lowe, M. C., Beasley, et al  
2024

- **Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec.** *JAAD case reports*  
Che, Y., Chong, C., Limova, M., Morris, L., Reddy, S. A., Chang, A. L.  
2024; 46: 92-94
- **Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma**  
Kirane, A., Lee, D., Ahmad, M., Sharma, S., Serasanambati, M., Lowe, M., Applebee, C., Safrygina, E., Swetter, S., Reddy, S., Warner, A., Funchain, P., Wang, et al  
SPRINGER.2024: S33-S34
- **ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?** *JACC. CardioOncology*  
Witteles, R. M., Reddy, S. A.  
2023; 5 (1): 133-136
- **Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.** *Cureus*  
Hui, C., Wu, Y. F., Liu, K., Sandhu, N., Blomain, E., Binkley, M. S., Gephart, M. H., Chang, S. D., Li, G. H., Reddy, S. A., Soltys, S. G., Pollom, E.  
2022; 14 (11): e31838
- **Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.** *The oncologist*  
Qian, M. F., Betancourt, N. J., Pineda, A., Maloney, N. J., Nguyen, K. A., Reddy, S. A., Hall, E. T., Swetter, S. M., Zaba, L. C.  
2022
- **Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.** *Circulation*  
Zhu, H., Galdos, F. X., Lee, D., Waliyany, S., Vivian Huang, Y., Ryan, J., Dang, K., Neal, J. W., Wakelee, H. A., Reddy, S. A., Srinivas, S., Lin, L. L., Witteles, et al  
2022: 101161CIRCULATIONAHA121056730
- **FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).**  
Zager, J. S., Orloff, M. M., Ferrucci, P., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, M. C., Reddy, S. A., Beasley, G., Gesierich, A., Dummer, R., Arance, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Thompson, J. A., Schneider, B. J., Brahmer, J., Achufusi, A., Armand, P., Berkenstock, M. K., Bhatia, S., Budde, L. E., Chokshi, S., Davies, M., Elshoury, A., Gesthalter, Y., Hegde, et al  
2022; 20 (4): 387-405
- **The complexity of carcinosarcoma.** *Oncology (Williston Park, N.Y.)*  
Reddy, S.  
1800; 35 (12): 814
- **Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma**  
Hui, C., Wu, Y., Liu, K., Sandhu, N., Blomain, E., Binkley, M., Gephart, M., Chang, S., Li, G., Reddy, S., Gibbs, I., Soltys, S., Pollom, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021: S48-S49
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**  
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.** *JAAD case reports*  
Hirotsu, K. E., Hua, V., Tran, A. T., Morris, L., Reddy, S. A., Kwong, B. Y., Zaba, L. C.  
2021; 13: 144-146
- **Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.**

Zager, J. S., Orloff, M., Ferrucci, P., Glazer, E., Ejaz, A., Richtig, E., Ochsenreither, S., Lowe, M. C., Reddy, S. A., Beasley, G., Gesierich, A., Dummer, R., Arance, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021

- **Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.** *Journal for immunotherapy of cancer*  
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A., Burgess, et al  
2021; 9 (4)
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*  
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.  
2021; 3 (1): 137–39
- **Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.** *Molecular cancer*  
Velez, G., Nguyen, H. V., Chemudupati, T., Ludwig, C. A., Toral, M., Reddy, S., Mruthyunjaya, P., Mahajan, V. B.  
2021; 20 (1): 39
- **Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A., Franc, B. L.  
2021
- **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis**  
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., Reddy, S., Heather, W., Neal, J. W., Witteles, R., Maecker, H. T., Davis, M., Nguyen, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy**  
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.  
SOC NUCLEAR MEDICINE INC.2020
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy**  
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.  
SOC NUCLEAR MEDICINE INC.2020
- **A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., Halpenny, D. F., Reddy, S. A., Vado, K. P., McCabe, D., Ramirez, K. A., Macri, M., Schwarzenberger, et al  
2020
- **Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.** *Melanoma management*  
Sodji, Q. H., Gutkin, P. M., Swetter, S. M., Reddy, S. A., Hiniker, S. M., Knox, S. J.  
2020; 7 (1): MMT36
- **Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.** *Cancer medicine*  
Hall, E., Zhang, J., Kim, E. J., Hwang, G., Chu, G., Bhatia, S., Reddy, S.  
2020
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*  
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al  
2020; 217 (9)
- **Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.** *World neurosurgery*

- Zhang, M. n., Rodrigues, A. J., Bhambhani, H. P., Fatemi, P. n., Pollom, E. L., Gibbs, I. C., Thomas, R. P., Soltys, S. G., Hancock, S. L., Chang, S. D., Reddy, S. A., Gephart, M. H., Li, et al  
2020
- **NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Kaffenberger, et al  
2020; 18 (3): 230–41
  - **"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma".** *American journal of ophthalmology case reports*  
Narala, R. n., Reddy, S. A., Mruthyunjaya, P. n.  
2020; 20: 100891
  - **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.** *European journal of nuclear medicine and molecular imaging*  
Nakamoto, R. n., Zaba, L. C., Rosenberg, J. n., Reddy, S. A., Nobashi, T. W., Davidzon, G. n., Aparici, C. M., Nguyen, J. n., Moradi, F. n., Iagaru, A. n., Franc, B. L.  
2020
  - **A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas**  
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., Reddy, S., Sarin, K., Colevas, D.  
MOSBY-ELSEVIER.2019: AB8
  - **Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.**  
Hall, E., Zhang, J., Kim, E., Hwang, G., Bhatia, S., Reddy, S. A.  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.**  
Amin, A., Milhem, M. M., Long, G. V., Hoimes, C. J., Medina, T., Conry, R., Lao, C. D., Daniels, G. A., Reddy, S. A., Andtbacka, R., Barve, M. A., Shaheen, M. F., Tueting, et al  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Management of Immunotherapy-Related Toxicities. Version 1.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Hoffner, et al  
2019; 17 (3): 255–88
  - **Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A. I., Burgess, et al  
2019: JCO1801896
  - **Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.** *Clinical nuclear medicine*  
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Torihara, A., Hatami, N., Yohannan, T. K., Mitra, E.  
2019
  - **Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up.** *Cureus*  
Gutkin, P. M., Hiniker, S. M., Swetter, S. M., Reddy, S. A., Knox, S. J.  
2018; 10 (12): e3723
  - **Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.** *Journal of the American Academy of Dermatology*  
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S. n., Jeng, M. n., Patel, R. n., Van der Bokke, L. n., Pague, A. n., Brotherton, R. n., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al  
2018
  - **Phase I Trial: SABR and Ipilimumab-Letter.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

- Hiniker, S. M., Reddy, S. A., Swetter, S. M., Knox, S. J.  
2017; 23 (1): 320
- **A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.** *International journal of radiation oncology, biology, physics*  
Hiniker, S. M., Reddy, S. A., Maecker, H. T., Subrahmanyam, P. B., Rosenberg-Hasson, Y., Swetter, S. M., Saha, S., Shura, L., Knox, S. J.  
2016; 96 (3): 578-588
  - **Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.** *Critical reviews in oncology/hematology*  
Reddy, S. A.  
2016; 106: 99-107
  - **PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma** *NEW ENGLAND JOURNAL OF MEDICINE*  
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, et al  
2016; 374 (26): 2542-2552
  - **Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases** *JOURNAL OF NEURO-ONCOLOGY*  
Li, Y., Pan, W., Connolly, I. D., Reddy, S., Nagpal, S., Quake, S., Gephart, M. H.  
2016; 128 (1): 93-100
  - **Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.** *Journal of biomedical informatics*  
Finlayson, S. G., Levy, M., Reddy, S., Rubin, D. L.  
2016; 60: 104-113
  - **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*  
Kim, Y. H., Tavallae, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al  
2015; 33 (32): 3750-3758
  - **Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.** *Journal of clinical oncology*  
Kim, Y. H., Tavallae, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., Rozati, S., Nagpal, S., Krathen, M., Reddy, S., Hoppe, R. T., Nguyen-Lin, A., Weng, et al  
2015; 33 (32): 3750-3758
  - **Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma** *LEUKEMIA & LYMPHOMA*  
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Waksman, J., Whittaker, S.  
2015; 56 (10): 2847-2854
  - **Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy.** *JAMA dermatology*  
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., Swetter, S. M.  
2014; 150 (11): 1209-1212
  - **Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy** *JAMA DERMATOLOGY*  
Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., Swetter, S. M.  
2014; 150 (11): 1209-1212
  - **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma** *BRITISH JOURNAL OF DERMATOLOGY*  
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.  
2013; 169 (3): 673-676
  - **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.** *British journal of dermatology*  
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.  
2013; 169 (3): 673-676
  - **A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy** *TRANSLATIONAL ONCOLOGY*

- Hiniker, S. M., Chen, D. S., Reddy, S., Chang, D. T., Jones, J. C., Mollick, J. A., Swetter, S. M., Knox, S. J.  
2012; 5 (6): 404-407
- **Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Whittaker, S. J., Demierre, M., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., Samtsov, A., McCulloch, W., Kim, et al  
2010; 28 (29): 4485-4491
  - **A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders** *CLINICAL CANCER RESEARCH*  
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., Lorenz, J., Sievers, E. L., Kim, Y. H.  
2009; 15 (19): 6217-6224
  - **Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome** *49th Annual Meeting of the American-Society-of-Hematology*  
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., Hoppe, R. T., Kim, Y. H.  
AMER MEDICAL ASSOC.2009: 667-74
  - **Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., Kim, Y. H.  
2008; 59 (6): 953-957
  - **Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinski, D. K., Vojdani, F., Hanley, K. M., Garger, S. J., White, E. L., Novak, J., Barrett, J., Holtz, R. B., Tuse, et al  
2008; 105 (29): 10131-10136
  - **Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas** *BRITISH JOURNAL OF HAEMATOLOGY*  
Reddy, S. A., Levy, R.  
2004; 124 (5): 626-628
  - **CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*  
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., Kim, Y. H.  
2003; 49 (6): 1049-1058
  - **T cell antigen receptor vaccines for active therapy of T cell malignancies** *Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma*  
Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R.  
NEW YORK ACAD SCIENCES.2001: 97-105
  - **Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., JOHNSTON, L. J., Long, G. D., Strober, S., Wong, R. M., Feiner, R. H., Kohler, S., Negrin, et al  
2000; 6 (5): 506-512